Latest Hotspot

FDA fast-tracks review of Merck's new WELIREG (belzutifan) drug submission for advanced kidney cancer patients

21 September 2023
3 min read

Merck, identified as MSD outside the US and Canada, has disclosed that the U.S. FDA has acknowledged and provided priority assessment for an auxiliary new drug application pursuing endorsement for WELIREG. This compound is Merck's oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, which is intended for the therapy of adult individuals with advanced renal cell carcinoma who have previously received immune checkpoint and anti-angiogenic therapies.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

The sNDA derives from the findings of the LITESPARK-005 study. The drug WELIREG showed a considerable and clinically relevant enhancement in PFS when compared to everolimus. This information was ascertained from a pre-established interim analysis overseen by an independent Data Monitoring Committee. There was also a notable improvement in the trial's main secondary endpoint, the objective response rate. The FDA assigned a target action date under the Prescription Drug User Fee Act, scheduled for January 17, 2024.

Dr. Marjorie Green, the senior vice president and head of late-stage oncology at Merck Research Laboratories, underscored that “There's a significant unmet need for different treatment options for patients with advanced RCC whose cancer worsens after immunological checkpoint and anti-angiogenic treatments, as they face a worse prognosis."

WELIREG made history as the first approved HIF-2α inhibitor therapy in the U.S., and it's authorized for adult patients with von Hippel-Lindau disease who need treatment for associated RCC, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors when immediate surgery isn't required.

LITESPARK-005 is part of an extensive development plan for WELIREG that includes four Phase 3 trials in RCC. These consist of LITESPARK-011 and LITESPARK-012, which assess WELIREG in second-line and treatment-naïve advanced disease scenarios, along with LITESPARK-022, which examines WELIREG in the adjuvant setting.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

According to the data provided by the Synapse Database, As of September 20, 2023, there are 19 investigational drugs for the HIF-2α target, including 25 indications,25 R&D institutions involved, with related clinical trials reaching 49and as many as 1251 patents.

Belzutifan targets HIF-2α and has shown promise in treating various diseases across multiple therapeutic areas. With its global approval in 2021 and ongoing phase 3 development in China, Belzutifan has the potential to make a significant impact in the field of biomedicine. Its regulatory designations further emphasize its importance in addressing critical medical needs.

图形用户界面, 文本

描述已自动生成

Analysis on the Research Progress of HSP90 inhibitors
Analysis on the Research Progress of HSP90 inhibitors
21 September 2023
Heat shock protein 90 (HSP90) is an ATP-dependent molecular chaperone essential in eukaryotic organisms.
Read →
European Commission approves Pfizer's LITFULO™ for Severe Alopecia Areata
Latest Hotspot
3 min read
European Commission approves Pfizer's LITFULO™ for Severe Alopecia Areata
21 September 2023
Pfizer Inc. confirmed the received marketing approval by the EC for LITFULO™ (ritlecitinib)  aimed for the treatment of severe alopecia areata in adults and adolescents aged 12 years and above.
Read →
The Clinical Application of Histamine Receptor Antagonists
The Clinical Application of Histamine Receptor Antagonists
21 September 2023
Histamine receptors are proteins found in various tissues throughout the human body.
Read →
Heidelberg Pharma Shares Progress Report for Phase I/IIa Clinical Study Involving HDP-101
Latest Hotspot
3 min read
Heidelberg Pharma Shares Progress Report for Phase I/IIa Clinical Study Involving HDP-101
21 September 2023
Heidelberg Pharma AG announced it began patient recruitment for the fifth group in the Phase I/IIa trial of their main development candidate, HDP-101, with a dose of 100 µg/kg.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.